Endometriosetherapie mit dem Destagen Diogenest
This prospective study investigated the therapeutic efficacy, tolerability, and side effect rate of Diogenest, an orally active gestagen, for treating endometriosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Full text
1,015 characters
· extracted from
oa-doi-fallback
· click to expand
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
Cited by (1)
References (1)
- Etiology and epidemiology of endometriosis via openalex
Cited by (1)
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00